Peptides for injury recovery: the evidence

Two peptides dominate the questions we get about injury recovery: BPC-157 and TB-500. Both are sold online as tissue-repair compounds, and both sit at very different points on the evidence ladder depending on what you ask them to do. This companion to our injury-recovery primer walks through what the published work actually supports for BPC-157 and TB-500, what rests on animal studies, and what is only anecdote.

Sort the evidence before you weigh it

A claim about a peptide is only as strong as the study design behind it. At the top sits the randomised controlled trial in humans, where a treatment is compared against placebo in real patients. Below that sits preclinical work in rats, mice and cell cultures, which can show a mechanism and a direction of effect but does not establish that the same thing happens in a person. Below that sits mechanistic plausibility, a reason to expect an effect that has not itself been measured as an outcome. At the bottom sits anecdote: forum posts, vendor testimonials and personal recovery stories, which record an experience but cannot separate the peptide from rest, physiotherapy, time, or placebo. For injury-recovery peptides, almost all of the marketing lives near the bottom of that ladder while being described as if it lived near the top.

BPC-157: strong animal data, no human trials

BPC-157 has an unusually large preclinical literature. Rodent studies report faster healing of transected tendons, ligaments and muscle, and the mechanistic story around new blood-vessel growth and growth-factor signalling is coherent. A 2019 review in Cell and Tissue Research summarised the tendon, ligament and muscle work and reached a blunt conclusion: "the majority of studies have been performed on small rodent models and the efficacy of BPC 157 is yet to be confirmed in humans."^[1] That sentence has not dated. There is still no published Phase 2 or Phase 3 randomised controlled trial of BPC-157 for any injury indication.

The regulatory record says the same thing in a different language. The US Anti-Doping Agency places BPC-157 on the WADA Prohibited List under S0, the category for substances not approved for human use by any regulator, and notes there is no legal basis for compounding pharmacies to use it^[2]. The US Department of Defense's Operation Supplement Safety programme is more direct about the evidence itself, stating that there is "little to no reliable scientific evidence to support the safety or effectiveness of BPC-157 in humans"^[3].

TB-500: one human trial, and it is for the eye

TB-500 is a trade label used for two related molecules: a synthetic heptapeptide and the full-length protein thymosin beta-4. Its preclinical file is also large, covering dermal, corneal, cardiac and neurological repair in animals. The important difference from BPC-157 is that thymosin beta-4 has produced Western-standard human trial data, but only in ophthalmology. A 2022 Phase 3 trial of the thymosin beta-4 eye drop RGN-259 in neurotrophic keratopathy randomised 18 patients and reported complete corneal healing at four weeks in 6 of 10 treated patients against 1 of 8 on placebo, a strong efficacy trend for a topical formulation^[4].

That result is real, and it is also the clearest example of why the evidence has to be read carefully. The trial tested a topical eye drop, made from the full-length peptide, in a corneal-surface condition. The injury-recovery use that drives grey-market demand is a subcutaneous injection, often of the shorter heptapeptide, aimed at tendons and muscle. None of those variables carry over automatically. The best human data for TB-500 does not speak to the reason most people actually buy it.

What we don't yet know

For the injury-recovery use case, the honest list of unknowns is long. There is no human dose-finding work to establish a therapeutic window, no long-term safety data, and no characterised picture of how either peptide interacts with existing conditions or medications. The cardiologist Eric Topol summarised the wider field in his Ground Truths newsletter: "The peptide craze is unfounded. The evidence base for use of these drugs, either for off-label indications or as non-approved drugs, is wanting."^[5] Anecdote fills the gap, but a recovery story cannot tell you whether the peptide did the work or whether time and rehabilitation did. Vendor pages that cite "studies" are almost always pointing at rat models, not at trials in people.

Where this leaves a careful reader

The preclinical signals for BPC-157 and TB-500 are genuine and worth following. They are also nowhere near the standard of evidence that supports an approved medicine, and neither peptide is licensed for injury recovery in any country we cover. If you want the per-compound detail, the BPC-157 page and the TB-500 page lay out the animal literature, the regulatory status, and the grey-market supply reality in full. This article is education, not medical advice, and the decision about whether either peptide belongs in a recovery plan is one to have with a clinician who knows your history.